Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.

Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.

Cancer. 2009 Jan 1;115(1):61-7. doi: 10.1002/cncr.24009.

2.

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K.

Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020. Review.

3.

[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].

Gschwend JE.

Onkologie. 2010;33 Suppl 1:10-1. doi: 10.1159/000265687. Epub 2010 Jan 22. Review. German.

PMID:
20164670
4.

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.

Merseburger AS, Simon A, Waalkes S, Kuczyk MA.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1429-34. doi: 10.1586/era.09.96. Review.

PMID:
19828003
5.

Update on systemic therapies of metastatic renal cell carcinoma.

Herrmann E, Bierer S, Wülfing C.

World J Urol. 2010 Jun;28(3):303-9. doi: 10.1007/s00345-010-0519-5. Epub 2010 Feb 24. Review.

PMID:
20180125
6.
7.

[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].

Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.

Aktuelle Urol. 2007 Jul;38(4):328-30. German.

PMID:
17647172
8.

Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.

Hiles JJ, Kolesar JM.

Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31. doi: 10.2146/ajhp060661. Review.

PMID:
18192256
9.

[Value of targeted therapies for renal cell cancer].

Merseburger AS, Kuczyk MA.

Urologe A. 2008 Oct;47(10):1303-10. doi: 10.1007/s00120-008-1746-x. Review. German.

PMID:
18587556
10.
11.

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J.

J Clin Oncol. 2010 May 1;28(13):2280-5. doi: 10.1200/JCO.2009.27.2757. Epub 2010 Mar 29. Review.

PMID:
20351323
12.

Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.

Breaker K, Naam M, La Rosa FG, Flaig IP, Flaig TW.

Dermatol Surg. 2013 Jul;39(7):981-7. doi: 10.1111/dsu.12184. Epub 2013 Mar 6. Review.

PMID:
23464361
13.

Prognostic markers and new, innovative treatments in renal cell carcinoma.

Secasan CC.

Saudi J Kidney Dis Transpl. 2009 May;20(3):355-61. Review.

14.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4. Review.

PMID:
19333228
15.

[Systemic treatment of renal cell carcinoma - recent update].

Grünberger B.

Wien Med Wochenschr. 2011 Aug;161(15-16):382-6. doi: 10.1007/s10354-011-0016-5. Review. German.

PMID:
21953429
16.
17.

Multi-target inhibitors in non-small cell lung cancer (NSCLC).

Tiseo M, Franciosi V, Ardizzoni A.

Ann Oncol. 2006 Mar;17 Suppl 2:ii55-57. Review. No abstract available.

PMID:
16608985
18.

Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.

Kroon BK, de Bruijn R, Prevoo W, Horenblas S, Powles T, Bex A.

Urology. 2013 Jan;81(1):111-5. doi: 10.1016/j.urology.2012.09.014. Epub 2012 Nov 13. Review.

PMID:
23153934
19.

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.

Wen T, Xiao H, Luo C, Huang L, Xiong M.

Oncotarget. 2017 Jan 15. doi: 10.18632/oncotarget.14671. [Epub ahead of print] Review.

Supplemental Content

Support Center